Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Five Years of Cancer Drug Approvals

Five Years of Cancer Drug Approvals Letters RESEARCH LETTER High profits may be justified if novel products offer sig- nificant benefits to patients (thus producing indirect eco- nomic value through the patients’ restored health) or if they Innovation, Efficacy, and Costs represent significant pharmacologic advances over their The price of cancer drugs has risen, drawing criticism from predecessors—offering new mechanisms of actions and 1,2 leading academics. The annual cost of a new cancer medi- emblematic of high-risk research. We investigated whether cation now routinely exceeds $100 000, and medical bills have novelty of medications or their relative benefits affected drug pricing. become the single largest cause of personal bankruptcy. Al- though some contend that the high cost of drugs is required to support re-search and development efforts, the fact re- Methods | We identified all oncologic drugs approved by the US mains that when costs and revenues are balanced, the phar- Food and Drug Administration (FDA) between January 1, 2009, maceutical industry generates high profit margins. and December 31, 2013. Oncologic drugs were approved based Table. Last 20 Oncologic Drugs Approved Between 2009 and 2013 by the US Food and Drug Administration Cost per Year of Drug and Indication Treatment, $ Parent Drug Mechanism of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Five Years of Cancer Drug Approvals

JAMA Oncology , Volume 1 (4) – Jul 1, 2015

Loading next page...
 
/lp/american-medical-association/five-years-of-cancer-drug-approvals-FzabxUB4wK

References (4)

  • Camille Abboud, Ellin Berman, Adam Cohen, J. Cortes, D. DeAngelo, M. Deininger, Steven Devine, B. Druker, Amir Fathi, E. Jabbour, M. Jagasia, H. Kantarjian, Jean Khoury, Pierre Laneuville, Richard Larson, Jeffrey Lipton, Joseph Moore, T. Mughal, Susan O’Brien, J. Pinilla-Ibarz, A. Quintás-Cardama, J. Radich, Vishnu Reddy, Charles Schiffer, Neil Shah, P. Shami, Richard Silver, David Snyder, Richard Stone, Moshe Talpaz, A. Tefferi, R. Etten, M. Wetzler, E. Abruzzese, J. Apperley, M. Breccia, Jenny Byrne, Francisco Cervantes, E. Chelysheva, Richard Clark, H. Lavallade, Iryna Dyagil, C. Gambacorti-Passerini, J. Goldman, İ. Haznedaroğlu, H. Hjorth-Hansen, T. Holyoake, B. Huntly, P. Coutre, E. Lomaia, F. Mahon, David Marin-Costa, Giovanni Martinelli, Jiří Mayer, D. Milojkovic, Eduardo Olavarria, K. Porkka, Johan Richter, Philippe Rousselot, G. Saglio, G. Saydam, J. Stentoft, A. Turkina, Paolo Vigneri, A. Zaritskey, Alvaro Aguayo, M. Ayala, Israel Bendit, R. Bengió, Carlos Best, Eduardo Bullorsky, E. Cervera, Carmino DeSouza, E. Fanilla, D. Gómez-Almaguer, N. Hamerschlak, Jose Lopez, A. Magariños, L. Meillon, J. Milone, B. Moiraghi, R. Pasquini, C. Pavlovsky, G. Ruiz-Argüelles, Nelson Spector, Christopher Arthur, P. Browett, Andrew Grigg, Jianda Hu, Xiao-jun Huang, T. Hughes, Qian Jiang, S. Jootar, Dong-Wook Kim, Hemant Malhotra, Pankaj Malhotra, I. Matsumura, Junia Melo, K. Ohnishi, Ryuzo Ohno, Tapan Saikia, A. Schwarer, N. Takahashi, Constantine Tam, Tetsuzo Tauchi, K. Usuki, Jianxiang Wang, Fawzi Abdel-Rahman, M. Aljurf, A. Bazarbachi, D. Yehuda, N. Chaudhri, M. Durosinmi, Hossam Kamel, Vernon Louw, B. Matti, A. Nagler, Pia Raanani, Ziad Salem (2013)

    The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

    Blood, 121 22

  • H. Kantarjian, T. Fojo, M. Mathisen, L. Zwelling (2013)

    Cancer drugs in the United States: Justum Pretium--the just price.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 28

  • P. Bach (2009)

    Limits on Medicare's ability to control rising spending on cancer drugs.

    The New England journal of medicine, 360 6

  • S. Mailankody, V. Prasad (2014)

    Comparative effectiveness questions in oncology.

    The New England journal of medicine, 370 16

Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2015.0373
pmid
26181265
Publisher site
See Article on Publisher Site

Abstract

Letters RESEARCH LETTER High profits may be justified if novel products offer sig- nificant benefits to patients (thus producing indirect eco- nomic value through the patients’ restored health) or if they Innovation, Efficacy, and Costs represent significant pharmacologic advances over their The price of cancer drugs has risen, drawing criticism from predecessors—offering new mechanisms of actions and 1,2 leading academics. The annual cost of a new cancer medi- emblematic of high-risk research. We investigated whether cation now routinely exceeds $100 000, and medical bills have novelty of medications or their relative benefits affected drug pricing. become the single largest cause of personal bankruptcy. Al- though some contend that the high cost of drugs is required to support re-search and development efforts, the fact re- Methods | We identified all oncologic drugs approved by the US mains that when costs and revenues are balanced, the phar- Food and Drug Administration (FDA) between January 1, 2009, maceutical industry generates high profit margins. and December 31, 2013. Oncologic drugs were approved based Table. Last 20 Oncologic Drugs Approved Between 2009 and 2013 by the US Food and Drug Administration Cost per Year of Drug and Indication Treatment, $ Parent Drug Mechanism of

Journal

JAMA OncologyAmerican Medical Association

Published: Jul 1, 2015

There are no references for this article.